US · Healthcare · Medical Devices
EPS came in at 0.17 against a street estimate of 0.17 — a beat of 0.0%.
Analysts rate Bioventus Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $17.60.
| Fund | Stake |
|---|---|
| Essex Woodlands Health Ventures | 19.06% |
| Nantahala Capital Management, LLC | 17.57% |
| Juniper Investment Co, LLC | 10.16% |
| BlackRock Inc | 5.03% |
| Royce & Associates, LP | 2.68% |
| Vanguard Capital Management, LLC | 2.56% |
| Geode Capital Management, LLC | 2.00% |
| American Century Companies Inc | 1.98% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 net sales were $142,442 thousand, up from $138,651 thousand in the third quarter of 2025. • Nine-month 2026 ne | 2026-11-02 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 revenue was $142.4 million, up 3% from $138.7 million in the prior-year period. • GAAP diluted earnings per share were $0 | 2026-11-02 |
| Quarterly report · Q2 2026 BIOVENTUS INC. - 10-Q SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Net Sales (6 months ended June 27, 2026): $285.3 million vs. $271.5 milli | 2026-08-05 |
| Results announced · Q3 2026 BIOVENTUS INC. – Q2 2026 FINANCIAL RESULTS SUMMARY --- HEADLINE NUMBERS • Q2 Revenue: $153.2 million, up 4% year-over-year • Q2 GAAP Earnings: $0.4 | 2026-08-05 |
| Shareholder vote results · Q2 2026 BIOVENTUS INC. (BVS) — FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 3, 2026 with 75,279,174 shares present or represented by proxy • | 2026-06-04 |
| Reg FD disclosure · Q2 2026 BIOVENTUS INC. (BVS) – FORM 8-K SUMMARY HEADLINE NUMBERS • FDA reclassified non-invasive bone growth stimulators from Class III to Class II devices | 2026-05-21 |
| Quarterly report · Q1 2026 BIOVENTUS INC. – Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Net sales Q1 2026: $132.1 million (vs $123.9 million Q1 2025) – up 6.6% year-over-year | 2026-05-06 |
| Results announced · Q2 2026 BIOVENTUS INC. - Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q1 2026 revenue: $132.1 million, up 7% year-over-year • GAAP earnings: $0.04 p | 2026-05-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Bioventus Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.